11/10/21 HC Wainwright Raises Price IVERIC bio, Inc. (ISEE) $20.00 âžť $26.00 Buy
S
This offering was basically an "institutional" placement. Given the continuing sloppiness of bio-related stocks, this offering came off quite easily in an "upsized mode.
Looking at the long-term chart, pretty clear sailing until overhead resistance encountered around $30.
j
(ISEE) reported a Q3 net loss of $0.23 per diluted share, narrower than the per-share loss of $0.27 a year earlier. Four analysts polled by Capital IQ projected a loss of $0.29 per share.
The biopharmaceutical company said it ended Q3 with $242 million of cash, cash equivalents, and marketable securities, up from $210 million at the end of last year.
J
blue sky to $30
Y
IVERIC bio reached a 52 Week high at 19.20
T
Looking good (no pun intended) this morning!
j
Oct. 21, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced that it is commencing an underwritten public offering of $125.0 million of shares of its common stock. In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of its common stock being offered. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares are to be offered by the Company.
j
Oct. 21, 2021-- IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an upsized underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $16.75 per share, less underwriting discounts and commissions. In addition, in connection with the offering, the Company has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,350,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by the Company.
The gross proceeds from the offering are expected to be approximately $150.8 million, before underwriting discounts and commissions and offering expenses payable by the Company, and without giving effect to any exercise by the underwriters of their option to purchase additional shares.
L
sometimes its hard to call if some biotechs will get approval, then sometimes the data is so good its just a foregone conclusion guess which one this is ??
L
October 19-21, 2021 | 9am - 5pm EST
Y
IVERIC bio reached a 52 Week high at 18.30
T
No difference in visual acuity between Sham and zimura
T
Tue, November 9, 2021, 6:30 AM In this article:
ISEE -2.35%
Zimura® GATHER2 Enrollment Complete; Retention Exceeding Expectations, with Injection Fidelity Rate Target of Greater than 90% -
People stay in a drug study because the drug's efficacy outweighs any side effects.
L
looks like they are being well received at the conference
L
base building great support in the 17s, to springboard higher
L
Zimura, a high-affinity, high-specificity pegylated RNA aptamer that binds human C5 prespecified primary efficacy endpoint was achieved for reduction in geographic atrophy (GA) growth rate vs. sham @ 12 months Zimura was well tolerated over 18 months
A
Why is this not tanking?
L
imo its a sign of the significant demand for this stock, the nuts over on stocktwits proclaiming the end is nigh were imo trying to get people to sell their stock so thir masters could scoop them up, i think people are holding this tight with a view to its future potential, so now tock offering to satisfy tute demand
T
I like what I SEE!
S
Hey Mark ("shorting is easy money" and "I can't wait to SHORT more tomorrow" posted on 9/11 and 9/13). How's that working out for you now with partnership likely and with (if) good PIII data, a NVS buyout rumors flouting around the Street? Sleeping well these nights? Easy money until it ain't.
HC Wainwright Raises Price IVERIC bio, Inc. (ISEE) $20.00 âžť $26.00 Buy
Looking at the long-term chart, pretty clear sailing until overhead resistance encountered around $30.
The biopharmaceutical company said it ended Q3 with $242 million of cash, cash equivalents, and marketable securities, up from $210 million at the end of last year.
The gross proceeds from the offering are expected to be approximately $150.8 million, before underwriting discounts and commissions and offering expenses payable by the Company, and without giving effect to any exercise by the underwriters of their option to purchase additional shares.
In this article:
ISEE
-2.35%
Zimura® GATHER2 Enrollment Complete; Retention Exceeding Expectations, with Injection Fidelity Rate Target of Greater than 90% -
People stay in a drug study because the drug's efficacy outweighs any side effects.
prespecified primary efficacy endpoint was achieved for reduction in geographic atrophy (GA) growth rate vs. sham @ 12 months
Zimura was well tolerated over 18 months